Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psilocybin + transcutaneous auricular vagus nerve stimulation
- Development stage
- Unknown
- Lead developer
- University of Wisconsin–Madison
- Modality
- Small Molecules
- Administration
- Oral, Transcutaneous
01
Overview
This therapeutic intervention consists of a combination of synthetic psilocybin and transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of major depressive disorder (MDD). Psilocybin is a serotonergic psychedelic that acts as a prodrug for psilocin, which primarily targets the 5-HT2A receptor to facilitate rapid neuroplasticity and profound psychological shifts. The taVNS component is a non-invasive medical device that delivers electrical stimulation to the auricular branch of the vagus nerve, aiming to modulate autonomic tone and enhance the therapeutic window provided by psilocybin. Developed by Dr. Charles Raison and investigated in the OPTIMIZE Phase 2 clinical trial, this approach explores whether neuromodulation can sustain or amplify the antidepressant effects of a single 25 mg psychedelic dose.
- Other names
- Psilocybin + taVNSOPTIMIZE Study Intervention
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)ABVN (Auricular branch of the vagus nerve)
Beyond the preview
Go deeper on psilocybin + transcutaneous auricular vagus nerve stimulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psilocybin + transcutaneous auricular vagus nerve stimulation.